Click Therapeutics

Summary active Updated May 26, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location New York, NY
Founded 2012
Latest Stage Series D
Total Raised $50M+
Website https://www.clicktherapeutics.com
Sector
healthtech digital-therapeutics

Investors

series-d (2026)
Lee Shapiro Board seat (2021)
7wire Ventures Board seat (2021)

Founders

David Benshoof Klein CEO & Founder

About

Click Therapeutics develops and commercializes software as prescription medical treatments for patients with unmet medical needs 1. The company focuses on digital therapeutics across psychiatry, neurology, oncology, immunology, and cardiometabolic diseases 1. Its FDA-authorized products include Rejoyn for Major Depressive Disorder and CT-132 for preventive treatment of episodic migraine 1. CT-155, an investigational prescription digital therapeutic for schizophrenia negative symptoms, received FDA Breakthrough Device designation in 2024 1.

Funding History

Date Round Amount Lead Co-investors
2026-04-09 Series D $50M Boehringer Ingelheim — 123

What Investors Say

No verified investor quotes available at this time.

What Founders Say

“Boehringer Ingelheim’s selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building.”

— David Benshoof Klein, CEO & Founder, Click Therapeutics 2

Sources

  1. GlobeNewsWire, “Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155,” April 9, 2026. https://www.globenewswire.com/news-release/2026/04/09/3270771/0/en/Click-Therapeutics-and-Boehringer-Ingelheim-Announce-Series-D-Investment-and-Funding-to-Advance-Commercialization-of-CT-155.html↩↩↩↩↩

  2. Click Therapeutics, “Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155,” April 9, 2026. Accessed May 2026. https://www.clicktherapeutics.com/news/click-therapeutics-and-boehringer-ingelheim-announce-series-d-investment-and-funding-to-advance-commercialization-of-ct-155↩↩

  3. BioSpace, “Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155,” April 9, 2026. Accessed May 2026. https://www.biospace.com/press-releases/click-therapeutics-and-boehringer-ingelheim-announce-series-d-investment-and-funding-to-advance-commercialization-of-ct-155↩